Assyro AI

FDA LETTER LIBRARY

Complete response & enforcement letters

One place to review FDA responses, identify remediation themes, and open the interactive co-pilot for every letter.

Showing 277-288 of 291 letters

ALApproval Letter

Approval Letter Other 206976 (Jan 1, 2018)

This document is an 'Other Action Letter' from the FDA regarding New Drug Application (NDA) 206976, outlining deficiencies that need to be addressed before the application can be approved. It details specific requirements related to biopharmaceutics, quality control, labeling, proprietary name, and safety updates.

IssuedJan 1, 2018
US FDA• Licart
ALApproval Letter

Approval Letter Other 207962 (Jan 1, 2018)

This is a Complete Response Letter from the FDA to Scilex Pharmaceuticals, Inc. regarding their New Drug Application (NDA) 207962 for ZTlido (lidocaine patch 1.8%). The FDA has determined that the application cannot be approved in its present form due to several deficiencies related to regulatory, clinical, clinical pharmacology, and nonclinical aspects.

IssuedJan 1, 2018
US FDA• ZTlido (lidocaine patch 1.8%)
ALApproval Letter

Approval Letter Other 207987 (Jan 1, 2018)

This is a Complete Response Letter from the FDA to Belcher Pharmaceuticals, LLC, for their New Drug Application (NDA) 207987 for Ablysinol (Dehydrated Alcohol Injection, USP). The FDA has determined that the application cannot be approved at the present time due to various deficiencies related to clinical data, product quality (CMC), prescribing information, proprietary name, and facility inspections. The letter outlines specific issues and provides suggestions for addressing them, including a mandatory postmarketing study.

IssuedJan 1, 2018
US FDA• Ablysinol (Dehydrated Alcohol Injection, USP)
ALApproval Letter

Approval Letter Other 208276 (Jan 1, 2018)

The FDA issued a Complete Response letter for New Drug Application (NDA) 208276 for the Implantable System for Remodulin (treprostinil) solution for injection, indicating that the application cannot be approved in its current form. The primary reasons for non-approval include the device component not being approvable, insufficient human factors data for safe and effective use, and insufficient data regarding the risk of microbial contamination in the implantable pump system.

IssuedJan 1, 2018
US FDA• Implantable System for Remodulin (treprostinil) solution for injection
ALApproval Letter

Approval Letter Other 208288 (Jan 1, 2018)

The FDA issued two Complete Response letters for New Drug Application (NDA) 208288 for SoluPrep™ to 3M Health Care. The letters detail reasons for non-approval, including nonclinical deficiencies related to impurity qualification and systemic toxicity assessment, requirements for a comprehensive safety update, and clinical deficiencies regarding replicative efficacy in pivotal studies and insufficient financial disclosure information for subinvestigators. The application cannot be approved in its present form, and specific actions are required for resubmission.

IssuedJan 1, 2018
US FDA• SoluPrep™ (2% chlorhexidine gluconate and 70% isopropyl alcohol), solution
ALApproval Letter

Approval Letter Other 208313 (Jan 1, 2018)

The FDA issued a Complete Response letter to Sun Pharmaceutical Industries Limited for their New Drug Application (NDA) for INFUGEM (gemcitabine injection), indicating that the application cannot be approved in its present form due to deficiencies identified during facility inspections and issues related to clinical data presentation and labeling.

IssuedJan 1, 2018
US FDA• INFUGEM (gemcitabine injection)
ALApproval Letter

Approval Letter Other 208647 (Jan 1, 2018)

This document is a Complete Response letter from the FDA to Salamandra, LLC regarding New Drug Application (NDA) 208647 for rosuvastatin capsules. The FDA has determined that the application cannot be approved in its present form due to deficiencies related to facility inspections, prescribing information, proprietary name, and safety update requirements.

IssuedJan 1, 2018
US FDA• rosuvastatin capsules, 5mg, 10mg, 20mg, and 40mg
ALApproval Letter

Approval Letter Other 208742 (Jan 1, 2018)

This document is a Complete Response letter from the FDA to Ocular Therapeutix, Inc. regarding their New Drug Application (NDA) 208742 for DEXTENZA (dexamethasone ophthalmic insert). The FDA has determined that the application cannot be approved in its current form due to deficiencies related to product quality/facilities inspection, prescribing information, proprietary name, and safety updates. The letter outlines specific issues and provides recommendations for addressing them.

IssuedJan 1, 2018
US FDA• DEXTENZA (dexamethasone ophthalmic insert), 0.4 mg
ALApproval Letter

Approval Letter Other 208564 (Jan 1, 2018)

The FDA issued a Complete Response letter for NDA 208564 for estradiol vaginal insert, indicating that the application cannot be approved in its current form due to deficiencies primarily related to clinical safety data, particularly long-term endometrial safety, and issues with labeling, safety updates, chemistry, manufacturing, controls, and carton/container labeling.

IssuedJan 1, 2018
US FDA• estradiol vaginal insert, 4, 10, mcg
ALApproval Letter

Approval Letter Other 208042 (Jan 1, 2018)

This is a Complete Response letter from the FDA to Teva Pharmaceuticals USA regarding their New Drug Application (NDA) 208042 for buprenorphine and naloxone sublingual film. The FDA has determined that the application cannot be approved in its present form due to deficiencies related to facility inspection, prescribing information, Medication Guide, Risk Evaluation and Mitigation Strategy (REMS), and safety update requirements.

IssuedJan 1, 2018
US FDA• buprenorphine and naloxone sublingual film, 16 mg/4 mg
ALApproval Letter

Approval Letter Other 209191 (Jan 1, 2018)

This document contains two Complete Response letters from the FDA to Hospira, Inc. regarding their New Drug Application (NDA) 209191 for Bortezomib for Injection. Both letters state that the application cannot be approved in its current form and outline deficiencies that need to be addressed for resubmission. The first letter (dated February 22, 2018) primarily focuses on product quality (elemental impurities), labeling, and safety update requirements. The second letter (dated November 3, 2017, though appearing later in the text) highlights deficiencies found during a manufacturing facility inspection, in addition to similar labeling and safety update requirements.

IssuedJan 1, 2018
US FDA• Bortezomib for Injection, 2.5 mg/vial
ALApproval Letter

Approval Letter Other 209311 (Jan 1, 2018)

This document is a Complete Response letter from the FDA to Ironshore Pharmaceuticals & Development, Inc. regarding their New Drug Application (NDA) 209311 for Jornay PM (methylphenidate hydrochloride) Modified Release Capsules. The FDA has determined that the application cannot be approved in its present form due to clinical safety concerns, specifically a high rate of insomnia, and outlines deficiencies and recommendations for resubmission.

IssuedJan 1, 2018
US FDA• Jornay PM (methylphenidate hydrochloride) Modified Release Capsules, 20 mg, 40 mg, 60 mg, 80 mg, and 100 mg

Page 24 of 25

Previous
1…22232425
Next